# A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea

> **NCT04470830** · — · COMPLETED · sponsor: **Celltrion Pharm, Inc.** · enrollment: 718 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04470830
- **Lead sponsor:** Celltrion Pharm, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-11
- **Primary completion:** 2023-05-25
- **Final completion:** 2023-05-25
- **Target enrollment:** 718 (ACTUAL)
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04470830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04470830, "A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04470830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*